JP2022547574A5 - - Google Patents

Info

Publication number
JP2022547574A5
JP2022547574A5 JP2022516046A JP2022516046A JP2022547574A5 JP 2022547574 A5 JP2022547574 A5 JP 2022547574A5 JP 2022516046 A JP2022516046 A JP 2022516046A JP 2022516046 A JP2022516046 A JP 2022516046A JP 2022547574 A5 JP2022547574 A5 JP 2022547574A5
Authority
JP
Japan
Prior art keywords
spik
sequence including
seq
amino acids
isolated antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022516046A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022547574A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/046782 external-priority patent/WO2021050217A1/en
Publication of JP2022547574A publication Critical patent/JP2022547574A/ja
Publication of JP2022547574A5 publication Critical patent/JP2022547574A5/ja
Priority to JP2025159797A priority Critical patent/JP2026012693A/ja
Pending legal-status Critical Current

Links

JP2022516046A 2019-09-11 2020-08-18 抗セリンプロテアーゼインヒビターkazal(spik)抗体のエピトープ Pending JP2022547574A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025159797A JP2026012693A (ja) 2019-09-11 2025-09-26 抗セリンプロテアーゼインヒビターkazal(spik)抗体のエピトープ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962899024P 2019-09-11 2019-09-11
US62/899,024 2019-09-11
PCT/US2020/046782 WO2021050217A1 (en) 2019-09-11 2020-08-18 Epitopes of anti-serine protease inhibitor kazal (spik) antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025159797A Division JP2026012693A (ja) 2019-09-11 2025-09-26 抗セリンプロテアーゼインヒビターkazal(spik)抗体のエピトープ

Publications (2)

Publication Number Publication Date
JP2022547574A JP2022547574A (ja) 2022-11-14
JP2022547574A5 true JP2022547574A5 (cg-RX-API-DMAC7.html) 2023-09-04

Family

ID=72243286

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022516046A Pending JP2022547574A (ja) 2019-09-11 2020-08-18 抗セリンプロテアーゼインヒビターkazal(spik)抗体のエピトープ
JP2025159797A Pending JP2026012693A (ja) 2019-09-11 2025-09-26 抗セリンプロテアーゼインヒビターkazal(spik)抗体のエピトープ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025159797A Pending JP2026012693A (ja) 2019-09-11 2025-09-26 抗セリンプロテアーゼインヒビターkazal(spik)抗体のエピトープ

Country Status (7)

Country Link
US (1) US20240043512A1 (cg-RX-API-DMAC7.html)
EP (1) EP4028132A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022547574A (cg-RX-API-DMAC7.html)
KR (1) KR20220080098A (cg-RX-API-DMAC7.html)
CN (1) CN114901699A (cg-RX-API-DMAC7.html)
CA (1) CA3150538A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021050217A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7658946B2 (ja) * 2019-07-08 2025-04-08 インケア バイオテック, エルエルシー カザール型抗セリンプロテアーゼ阻害因子(spik)抗体、免疫複合体、及び使用方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
EP0731106B1 (en) 1993-10-01 2004-11-17 Teikoku Hormone Mfg. Co., Ltd. Dolastatin derivatives
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6248564B1 (en) 1997-08-29 2001-06-19 Harvard University Mutant MHC class I molecules
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20050123536A1 (en) 2001-11-20 2005-06-09 Che-Leung Law Treatment of immunological disorders using anti-dc30 antibodies
CA2494104A1 (en) 2002-07-31 2004-04-22 Seattle Genetics, Inc. Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
CN101970498A (zh) * 2007-10-25 2011-02-09 维文蒂阿生物技术公司 针对变体HnRNPG的癌相关表位的抗体及其应用
PE20120877A1 (es) 2009-04-01 2012-08-06 Genentech Inc ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS
US20140308657A1 (en) * 2010-12-09 2014-10-16 Philadelphia Health & Education Corporation D/B/A Drexel University College Of Medicine Serine protease inhibitor kazal antibodies
CN104994875B (zh) * 2013-02-15 2018-10-09 免疫医疗公司 嵌合和人源化抗组蛋白抗体
US10746742B2 (en) * 2014-04-25 2020-08-18 Oregon Health & Science University Methods of viral neutralizing antibody epitope mapping
AU2017239637A1 (en) * 2016-03-29 2018-11-15 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
CN120005029A (zh) 2018-03-06 2025-05-16 英凯尔生物科技有限责任公司 丝氨酸蛋白酶抑制剂Kazal(SPIK)组合物和方法
CN109678950B (zh) * 2019-01-08 2022-05-10 灏灵赛奥(天津)生物科技有限公司 spink1抗原、能够特异性结合spink1的抗体及其功能片段及其应用和产品
JP7658946B2 (ja) * 2019-07-08 2025-04-08 インケア バイオテック, エルエルシー カザール型抗セリンプロテアーゼ阻害因子(spik)抗体、免疫複合体、及び使用方法

Similar Documents

Publication Publication Date Title
RU2504551C2 (ru) Белки, связывающие антиген фактор роста, подобный гепаринсвязывающему эпидермальному фактору роста
CN102421795B (zh) 针对肌钙蛋白i的抗体及其使用方法
US10197573B2 (en) HCV core lipid binding domain monoclonal antibodies
JP4287280B2 (ja) HCVE2グリコプロテインに対して向けられ、invitro中和活性を有するヒトモノクローナル抗体Fab断片
CN102906113B (zh) 治疗性dll4结合蛋白
JP2007527406A5 (cg-RX-API-DMAC7.html)
FI3718564T3 (fi) Uusia anti-IL 13 -vasta-aineita ja niiden käyttöjä
JP2020516603A5 (cg-RX-API-DMAC7.html)
JP2009517057A5 (cg-RX-API-DMAC7.html)
JP2005528914A5 (cg-RX-API-DMAC7.html)
RU2007118670A (ru) Ангиопоэтин-2-специфические связывающие агенты
EP3983806A1 (en) Multiplex competition assay for profiling binding epitopes of affinity agents for clinical diagnostics use
JP2023518225A5 (cg-RX-API-DMAC7.html)
JP2025111457A5 (cg-RX-API-DMAC7.html)
JP2020189843A5 (cg-RX-API-DMAC7.html)
JP2021515597A5 (cg-RX-API-DMAC7.html)
JP2022540079A5 (cg-RX-API-DMAC7.html)
CN114650866B (zh) 新的用于诊断的分子
JP5821198B2 (ja) 抗il28b抗体及びこれを用いたil28bの測定方法
KR102078879B1 (ko) 돼지파보바이러스에 특이적인 단일클론항체 및 이의 용도
WO2024093042A1 (zh) 一种抗bsa的兔单克隆抗体及其应用
WO2022238481A1 (en) Antibodies
KR20230124280A (ko) 메르스 코로나 바이러스의 뉴클레오캡시드 단백질에 특이적인 진단용 항체 및 이의 용도
CN115210256A (zh) 用于前列腺癌诊断的新方法和化合物
JP2023156197A5 (cg-RX-API-DMAC7.html)